CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
1.5 هزار بار بازدید -
5 سال پیش
-
Prof Ronald de Wit speaks
Prof Ronald de Wit speaks to ecancer at ESMO 2019 in Barcelona about the CARD study.
He outlines the background and study design, and the premise for this particular design.
Prof de Wit explains the positive results, and also the robust nature of the data. He believes that cabazitaxel will be practise changing, and is well tolerated.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
He outlines the background and study design, and the premise for this particular design.
Prof de Wit explains the positive results, and also the robust nature of the data. He believes that cabazitaxel will be practise changing, and is well tolerated.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
5 سال پیش
در تاریخ 1398/07/18 منتشر شده
است.
1,547
بـار بازدید شده